Trials / Completed
CompletedNCT00536965
Percentage of Secondary Prevention Patients Treated to Their LDL-C Targets
Non-interventional Study Investigating How Effective Secondary Prevention Patients Are Treated to Their LDL-C Targets
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 951 (actual)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
A cholesterol/lipid profile screening project of high risk patients with hyperlipidaemia (secondary prevention) who already receive cholesterol-lowering therapy. Lipid profile and rate of patients who are treated to target (which is \<100mg/dl for patients with high risk and \<70mg/dl for patients at very high risk) are screened (office-based specialists). The doctors therapy decisions after the screening and possible reasons for these decisions will be documented. Our aim is to evaluate dosing habits, to evaluate how many patients are treated to their LDL-C target and to underline the importance of treating patients to their cholesterol targets.
Conditions
- Hyperlipidemias
- Atherosclerosis
- Coronary Heart Disease
- Carotid Stenosis
- Peripheral Vascular Diseases
- Diabetes Mellitus
Timeline
- Start date
- 2007-07-01
- Primary completion
- 2007-12-01
- Completion
- 2007-12-01
- First posted
- 2007-09-28
- Last updated
- 2014-10-30
Locations
1 site across 1 country: Austria
Source: ClinicalTrials.gov record NCT00536965. Inclusion in this directory is not an endorsement.